CN105250366A - 香青兰提取物及其制备方法和用途 - Google Patents
香青兰提取物及其制备方法和用途 Download PDFInfo
- Publication number
- CN105250366A CN105250366A CN201510652848.7A CN201510652848A CN105250366A CN 105250366 A CN105250366 A CN 105250366A CN 201510652848 A CN201510652848 A CN 201510652848A CN 105250366 A CN105250366 A CN 105250366A
- Authority
- CN
- China
- Prior art keywords
- ethanol
- water
- herba dracocephali
- eluting
- medical material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000284 extract Substances 0.000 title claims abstract description 68
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 238000000605 extraction Methods 0.000 title claims description 14
- 244000179525 Dracocephalum moldavica Species 0.000 title abstract description 12
- 235000010700 Dracocephalum moldavica Nutrition 0.000 title abstract description 12
- 229930003944 flavone Natural products 0.000 claims abstract description 21
- 235000011949 flavones Nutrition 0.000 claims abstract description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 287
- 229960004756 ethanol Drugs 0.000 claims description 136
- 241001529849 Dracocephalum Species 0.000 claims description 92
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 78
- 239000012567 medical material Substances 0.000 claims description 76
- 239000003480 eluent Substances 0.000 claims description 75
- 238000010992 reflux Methods 0.000 claims description 71
- 239000002253 acid Substances 0.000 claims description 57
- 229930182470 glycoside Natural products 0.000 claims description 55
- 150000002338 glycosides Chemical class 0.000 claims description 55
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 49
- 239000011347 resin Substances 0.000 claims description 40
- 229920005989 resin Polymers 0.000 claims description 40
- 239000000843 powder Substances 0.000 claims description 35
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 claims description 28
- 238000001035 drying Methods 0.000 claims description 25
- 238000010521 absorption reaction Methods 0.000 claims description 23
- 239000007788 liquid Substances 0.000 claims description 18
- 208000029078 coronary artery disease Diseases 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 16
- 239000000706 filtrate Substances 0.000 claims description 16
- 238000005406 washing Methods 0.000 claims description 16
- 239000003463 adsorbent Substances 0.000 claims description 15
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 15
- 239000006210 lotion Substances 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 claims description 14
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 claims description 14
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 claims description 14
- 150000002213 flavones Chemical class 0.000 claims description 13
- 239000008367 deionised water Substances 0.000 claims description 10
- 229910021641 deionized water Inorganic materials 0.000 claims description 10
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 9
- 206010002383 Angina Pectoris Diseases 0.000 claims description 5
- 239000003643 water by type Substances 0.000 claims description 5
- 208000031225 myocardial ischemia Diseases 0.000 abstract description 19
- 241000700159 Rattus Species 0.000 abstract description 14
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 abstract description 8
- 150000002212 flavone derivatives Chemical class 0.000 abstract description 8
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 abstract description 8
- 230000006378 damage Effects 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 7
- 230000001681 protective effect Effects 0.000 abstract description 5
- 239000000243 solution Substances 0.000 description 58
- 210000002216 heart Anatomy 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 239000013558 reference substance Substances 0.000 description 14
- 238000012360 testing method Methods 0.000 description 13
- 239000004744 fabric Substances 0.000 description 12
- 239000002245 particle Substances 0.000 description 12
- 230000009286 beneficial effect Effects 0.000 description 10
- 238000000034 method Methods 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 6
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 6
- 210000004351 coronary vessel Anatomy 0.000 description 6
- 238000005457 optimization Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000010410 reperfusion Effects 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 206010042434 Sudden death Diseases 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 206010069729 Collateral circulation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000002605 anti-dotal effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012490 blank solution Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510652848.7A CN105250366B (zh) | 2015-10-10 | 2015-10-10 | 香青兰提取物及其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510652848.7A CN105250366B (zh) | 2015-10-10 | 2015-10-10 | 香青兰提取物及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105250366A true CN105250366A (zh) | 2016-01-20 |
CN105250366B CN105250366B (zh) | 2020-03-13 |
Family
ID=55090502
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510652848.7A Expired - Fee Related CN105250366B (zh) | 2015-10-10 | 2015-10-10 | 香青兰提取物及其制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105250366B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106822165A (zh) * | 2015-11-24 | 2017-06-13 | 石河子大学医学院第附属医院 | 刺槐素‑7‑o‑葡萄糖醛酸苷的用途 |
CN107586311A (zh) * | 2017-07-25 | 2018-01-16 | 贵州维康子帆药业股份有限公司 | 酢浆草中提取刺槐素‑6‑C‑β‑D‑葡萄糖苷的方法 |
CN109810158A (zh) * | 2019-03-01 | 2019-05-28 | 新疆维吾尔自治区药物研究所 | 香叶木素-7-o-葡萄糖醛酸苷的制备方法 |
RU2695328C1 (ru) * | 2018-09-25 | 2019-07-23 | Федеральное государственное бюджетное научное учреждение Всероссийский научно-исследовательский институт лекарственных и ароматических растений (ФГБНУ ВИЛАР) | СПОСОБ ПОЛУЧЕНИЯ ЛЕКАРСТВЕННЫХ СУБСТАНЦИЙ ИЗ ЗМЕЕГОЛОВНИКА МОЛДАВСКОГО (Dracocephalum moldavica L.) |
CN113633675A (zh) * | 2021-09-28 | 2021-11-12 | 新疆维吾尔自治区药物研究所 | 香青兰提取物在制备抗心脏毒性作用药物中的应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1488638A (zh) * | 2002-10-10 | 2004-04-14 | 上海海天医药科技开发有限公司 | 淫羊藿总黄酮的提取方法及其提取物所制成的产品 |
CN101219161A (zh) * | 2007-12-25 | 2008-07-16 | 新疆维吾尔自治区药物研究所 | 香青兰提取物和香青兰滴丸及其生产方法 |
-
2015
- 2015-10-10 CN CN201510652848.7A patent/CN105250366B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1488638A (zh) * | 2002-10-10 | 2004-04-14 | 上海海天医药科技开发有限公司 | 淫羊藿总黄酮的提取方法及其提取物所制成的产品 |
CN101219161A (zh) * | 2007-12-25 | 2008-07-16 | 新疆维吾尔自治区药物研究所 | 香青兰提取物和香青兰滴丸及其生产方法 |
Non-Patent Citations (3)
Title |
---|
于宁等: "香青兰提取物中苯丙素类和黄酮类3个化合物的含量测定", 《中国药学杂志》 * |
王铮涛等: "《中药化学》", 30 September 2009, 上海科学技术出版社 * |
翁剑锋等: "维药香青兰研究新进展", 《江西中医学院学报》 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106822165A (zh) * | 2015-11-24 | 2017-06-13 | 石河子大学医学院第附属医院 | 刺槐素‑7‑o‑葡萄糖醛酸苷的用途 |
CN106822165B (zh) * | 2015-11-24 | 2020-08-11 | 石河子大学医学院第一附属医院 | 刺槐素-7-o-葡萄糖醛酸苷的用途 |
CN107586311A (zh) * | 2017-07-25 | 2018-01-16 | 贵州维康子帆药业股份有限公司 | 酢浆草中提取刺槐素‑6‑C‑β‑D‑葡萄糖苷的方法 |
CN107586311B (zh) * | 2017-07-25 | 2018-10-09 | 贵州维康子帆药业股份有限公司 | 酢浆草中提取刺槐素-6-C-β-D-葡萄糖苷的方法 |
RU2695328C1 (ru) * | 2018-09-25 | 2019-07-23 | Федеральное государственное бюджетное научное учреждение Всероссийский научно-исследовательский институт лекарственных и ароматических растений (ФГБНУ ВИЛАР) | СПОСОБ ПОЛУЧЕНИЯ ЛЕКАРСТВЕННЫХ СУБСТАНЦИЙ ИЗ ЗМЕЕГОЛОВНИКА МОЛДАВСКОГО (Dracocephalum moldavica L.) |
CN109810158A (zh) * | 2019-03-01 | 2019-05-28 | 新疆维吾尔自治区药物研究所 | 香叶木素-7-o-葡萄糖醛酸苷的制备方法 |
CN109810158B (zh) * | 2019-03-01 | 2021-06-11 | 新疆维吾尔自治区药物研究所 | 香叶木素-7-o-葡萄糖醛酸苷的制备方法 |
CN113633675A (zh) * | 2021-09-28 | 2021-11-12 | 新疆维吾尔自治区药物研究所 | 香青兰提取物在制备抗心脏毒性作用药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN105250366B (zh) | 2020-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105250366A (zh) | 香青兰提取物及其制备方法和用途 | |
WO2004009575A1 (en) | An extract of a typhae pollen and its manufacture and use | |
CN101311160B (zh) | 一种丹参丹酚酸a的制备方法 | |
CN101230003B (zh) | 一种丹参丹酚酸a的制备方法 | |
CN104435034A (zh) | 一种三七总皂苷及其制备方法 | |
CN102309542B (zh) | 用于慢性肾炎的肾茶正丁醇部位药及其制备方法 | |
CN101006984B (zh) | 一种丹参丹酚酸a、三七提取物的注射制剂及其制备方法和应用 | |
CN100377731C (zh) | 一种中药及其制备方法和用途 | |
CN102100737B (zh) | 包含人参总皂苷与丹参总酚酸的药物组合物及其制备方法 | |
CN100467025C (zh) | 积雪草总苷、积雪草苷或羟基积雪草苷在制备防治心、脑血管疾病药物中的用途 | |
CN105687262A (zh) | 一种银杏叶酊剂及其制备方法 | |
CN103908571B (zh) | 一种治疗心脏疾病的复方中药制剂 | |
CN109939106A (zh) | 驱虫斑鸠菊中分离的倍半萜类化合物在制备治疗白癜风的药物中的用途 | |
CN113350396B (zh) | 一种抗心肌缺血中药组合物的制备方法 | |
CN104622932A (zh) | 一种治疗心肌缺血的中药及其制备方法与检测方法及应用 | |
CN1994277B (zh) | 一种丹参丹酚酸a固体制剂及其制备方法 | |
CN103919759B (zh) | 一种含有丹参素钠、丹参丹酚酸f的药物组合物及其制剂 | |
CN101036637B (zh) | 丹参酮ⅰ磺酸钠在制备药物中的应用 | |
CN102100721A (zh) | 一种亳菊总黄酮的生产方法 | |
CN101759751A (zh) | 含有杂质人参皂苷Re的人参皂苷Rg1 | |
CN101744938B (zh) | 一种药物组合物及其制备方法 | |
CN101088532A (zh) | 治疗中风和胸痹的中药制剂及其制法和质量控制方法 | |
CN1582946B (zh) | 积雪草酸衍生物在制备防治心、脑血管疾病的药物中的用途 | |
CN1965849B (zh) | 从中药中提取用于治疗冠心病的组合物及组分制备方法 | |
CN101088548B (zh) | 治疗心律失常的中药制剂及其制法和质量控制方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Xing Jianguo Inventor after: He Chenghui Inventor after: Yu Ning Inventor after: Zheng Ruifang Inventor after: Liu Xuanlin Inventor after: Ruxian Guli. Yiming Inventor before: Xing Jianguo Inventor before: He Chenghui Inventor before: Yu Ning Inventor before: Jiang Wen Inventor before: Liu Xuanlin Inventor before: Ruxian Guli. Yiming |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200313 |